Categories AlphaGraphs, Earnings, Health Care
AngioDynamics (ANGO) reports net loss for Q2 2025; sales drop 8%
AngioDynamics Inc. (NASDAQ: ANGO) reported a net loss for the second quarter of 2025 as the medical device company’s revenues decreased 8%.
Net loss, excluding special items, was $0.04 per share in the November quarter, compared to a loss of $0.05 per share in the corresponding period of 2024. On an unadjusted basis, net loss narrowed to $10.7 million or $0.26 per share in Q2 from $29 million or $0.72 per share in the prior-year quarter.
Revenues, on a reported basis, decreased 8% year-over-year to $72.8 million in the second quarter. The company continues to expect fiscal 2025 sales in the range of $282 million to $288 million.
Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “We are very excited about our strong performance during the second quarter, and in particular the continued strength of our Med Tech segment,
which grew 25% over the prior year.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
NeOnc Technologies plans to go public through direct listing
NeOnc Technologies Holdings Inc., a privately held clinical-stage biotechnology company that develops therapies to improve the treatment of brain tumors and central nervous system diseases, is preparing to become a
Chewy (CHWY): A few factors that work in favor of this pet supplies retailer
Shares of Chewy, Inc. (NYSE: CHWY) were down over 1% on Tuesday. The stock has gained 72% over the past 12 months. The company delivered sales and earnings growth for
Amazon looks set for another strong year as cloud and ads boom
Taking a cue from the AI frenzy, Amazon.com Inc. (NASDAQ: AMZN) has adopted a growth strategy focused on expanding generative AI capabilities, through initiatives like the recent expansion of its
